Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806244 | 0.88 | SCN9A (0.46) | HSD11B1MGLLSCN9ACACNA1BAKR1C3 | |
| SCHEMBL1810294 | 0.84 | SCN9A (0.45) | HSD11B1MGLLSCN9ACACNA1BAKR1C3 | |
| SCHEMBL12100616 | 0.77 | METAP1 (0.35) | MGLL | |
| SCHEMBL1807553 | 0.75 | SCN9A (0.47) | HSD11B1MGLLSCN9ACACNA1BAKR1C3 | |
| SCHEMBL1807752 | 0.74 | EPHX2 (0.49) | MGLLSCN9APIM1KMT2A | |
| SCHEMBL12099414 | 0.74 | HSD11B1 (0.46) | HSD11B1MGLLSCN9ACACNA1B | |
| SCHEMBL12188766 | 0.73 | SPR (0.44) | MGLLPIM1KDM4EKMT2A | |
| SCHEMBL1811165 | 0.73 | CCKAR (0.40) | SCN9ACCKARPIM1PRKAA2 | |
| SCHEMBL1807022 | 0.72 | HRH3 (0.46) | PIM1KDM4EKMT2APRKAA2 | |
| SCHEMBL1806800 | 0.72 | HRH3 (0.50) | PIM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HSD11B1 2985/4885MGLL 4513/4885SCN9A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.